We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05185284
Recruitment Status : Completed
First Posted : January 11, 2022
Last Update Posted : January 11, 2022
Sponsor:
Collaborator:
Solyur Pharmaceuticals Group
Information provided by (Responsible Party):
Promomed, LLC

Brief Summary:
This is open-labe randomized multicenter comparative Phase III study conducted in 7 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir for parenteral administration compared with the Standard of care (SOC) in hospitalized patients with moderate COVID-19 pneumonia.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Favipiravir Drug: Remdesivir Phase 3

Detailed Description:
Upon signing the informed consent form and screening, 217 eligible patients hospitalized with COVID-19 pneumonia were randomized at a 1:1 ratio to receive either Favipiravir intravenously by drip infusion for 2 hours 1600 mg twice a day (BID) on Day 1 followed by 800 mg BID on Days 2-14 (1600/800 mg), or SOC. The course of treatment by Favipiravir is 10 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 217 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of AREPLIVIR® (Favipiravir) for Parenteral Administration (PROMOMED RUS LLC, Russia) in Hospitalized Patients With COVID-19
Actual Study Start Date : August 11, 2021
Actual Primary Completion Date : December 30, 2021
Actual Study Completion Date : December 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Favipiravir (Areplivir)
Arm 1 (n=106) receives the study drug Areplivir for parenteral administration as follows: Day 1 1600 mg 2 times a day, Day 2-10 800 mg 2 times a day. Administration will be done intravenously by drip infusion for 2 hours. The course of treatment is 10 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient.
Drug: Favipiravir
400 mg, lyophilizate for preparation of concentrate for solution for infusion
Other Name: Areplivir

Active Comparator: Standard of care

Arm 2 (n=108) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health by decision of the investigator and taking into account the availability of drugs at the study site. Might include Favipiravir tab, Remdesivir or other recommended schemes.

Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime.

Drug: Favipiravir
200 mg coated tablets

Drug: Remdesivir
100 mg, lyophilizate for preparation of concentrate for solution for infusion




Primary Outcome Measures :
  1. Rate of Clinical Status Improvement [ Time Frame: By Visit 3, approximately 10 days ]
    Rate of clinical status improvement by WHO categorical ordinal scale of clinical status improvement by 2 or more categories by Day 10. WHO Ordinal Scale for Clinical Improvement (WHO-OSCI), 0 - uninfected (There are no clinical and virological signs of infection), 8 - dead, higher scores mean a worse outcome

  2. Time to Clinical Improvement [ Time Frame: 28 days ]
    Time (in days) to improvement in clinical status by WHO categorical ordinal scale of clinical status improvement


Secondary Outcome Measures :
  1. Rate of Clinical Status Improvement [ Time Frame: 14 days ]
    Rate of clinical status improvement by WHO categorical ordinal scale of clinical status improvement by 2 or more categories at Visits 2 (Day 5) and 4 (Day 14)

  2. Rate of Clinical Status Improvement [ Time Frame: 14 Days ]
    Percentage of patients with clinical status of 0 and 1 point according to the WHO categorical ordinal scale of clinical improvement on Days 5, 10 and 14.

  3. End of Fever on Days of study [ Time Frame: 14 Days ]
    Percentage of patients with fever disappearance (body temperature < 37,2 °C in 3 consecutive measurements without antipyretic medication) an Days 5, 10 and 14.

  4. Change in the Level of Lung Damage According to CT [ Time Frame: 14 Days ]
    Assessment of lung injury (degree of damage by "empirical" visual scale and % of patients) according to CT data comparing to baseline. The number of patients in whom by the end of therapy there was an improvement in the condition of the lungs (a decrease in the volume of the lesion according to CT)

  5. Rate of Viral Elimination [ Time Frame: 14 days ]
    Percentage of patients with SARS-CoV-2 elimination (negative test for SARS-CoV-2 by NAA method) on Days 5, 10, and 14.

  6. Rate of Transfer to the Intensive Care Unit [ Time Frame: 28 days ]
    Percentage of patients transferred to intensive care unit

  7. Rate of the Use of Non-invasive Lung Ventilation [ Time Frame: 28 Days ]
    Percentage of cases with non-invasive lung ventilation

  8. Rate of the Use of Mechanical Ventilation [ Time Frame: 28 Days ]
    Percentage of cases with mechanical lung ventilation (% of patients)

  9. Mortality [ Time Frame: 28 Days ]
    Incidence of fatal cases (% of patients)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Availability of the Informed Consent Form of the Patient Information Leaflet (PIL) signed and dated by patient.
  2. Men and women aged 18 to 80 years inclusive at the time of signing the Informed Consent Form in PIL.
  3. Confirmed case of COVID-19 at the time of screening based on SARS-CoV-2 RNA test using nucleic acid amplification (NAA) method. It is acceptable to include a patient with a presumptive COVID-19 diagnosis prior to receiving the results of SARS-CoV-2 RNA test made at the screening stage.
  4. Hospital admission due to COVID-19.
  5. Moderate severity infection with SARS-CoV-2:

    • Clinical signs:
    • Mandatory: CT pattern typical of a viral lesion (lesion volume is minimal or moderate; CT 1-2).
    • Additional (at least 1 of the following criteria):
    • body temperature > 38 °C;
    • RR > 22/min;
    • shortness of breath on exertion;
    • SpO2 < 95%;
    • Serum CRP > 10 mg/L.
  6. Patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. Reliable means of contraception are: sexual abstinence, use of condom in combination with spermicide.

For men (optional): Consent to avoid sexual contact with pregnant women for the duration of the study and for 3 months after its completion.

Women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as men with infertility or a history of vasectomy.

Exclusion Criteria:

  1. Hypersensitivity to favipiravir, remdesivir and/or other components of the study drug.
  2. Impossibility of CT procedure (for example, gypsum dressing or metal structures in the field of imaging).
  3. History of vaccination against COVID-19.
  4. History of presumptive or confirmed COVID-19 case of moderate, severe and extremely severe course of the disease.
  5. Use of favipiravir or remdesivir within 10 days prior to screening.
  6. The need to use drugs from the list of prohibited therapy.
  7. Meeting the criteria for severe and extremely severe course of the disease.
  8. Need for treatment in the intensive care unit.
  9. Impaired liver function (AST and/or ALT ≥ 2 UNL and/or total bilirubin ≥ 1.5 UNL) at the time of screening.
  10. Renal impairment (GFR < 60 ml/min) at the time of screening.
  11. History of gout.
  12. Positive testing for HIV, syphilis, hepatitis B and/or C.
  13. Chronic heart failure FC III-IV according to New York Heart Association (NYHA) functional classification (see Appendix 2).
  14. Malignancies in the past medical history.
  15. Alcohol, pharmacological and/or drug addiction in the past medical history and/or at the time of screening.
  16. Schizophrenia, schizoaffective disorder, bipolar disorder, or other history of mental pathology or suspicion of their presence at the time of screening.
  17. Severe, decompensated or unstable somatic diseases (any disease or condition that threaten the patient's life or impair the patient's prognosis, and also make it impossible for him/her to participate in the clinical study).
  18. Any history data that the investigating physician believes could lead to complication in the interpretation of the study results or create an additional risk to the patient as a result of his/her participation in the study.
  19. Patient's unwillingness or inability to comply with procedures of the Study Protocol (in the opinion of physician investigator).
  20. Pregnant or nursing women or women planning pregnancy.
  21. Participation in another clinical study for 3 months prior to inclusion in the study.
  22. Other conditions that, according to the physician investigator, prevent the patient from being included in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05185284


Locations
Layout table for location information
Russian Federation
Regional budgetary health care institution "Ivanovo Clinical Hospital named after Kuvaevs"
Ivanovo, Russian Federation, 153025
State Budgetary Institution of Healthcare of the City of Moscow "City Clinical Hospital No. 24 of the Department of Healthcare of the City of Moscow"
Moscow, Russian Federation, 127015
State Clinical Hospital №50
Moscow, Russian Federation
Regional Clinic Hospital of Ryazan
Ryazan', Russian Federation
Medical institute Ogarev Mordovia State university
Saransk, Russian Federation
Smolensk clinical hospital №1
Smolensk, Russian Federation
Sponsors and Collaborators
Promomed, LLC
Solyur Pharmaceuticals Group
Investigators
Layout table for investigator information
Principal Investigator: Dmitriy Pushkar, MD, Academic Moscow State Clinical Hospital №50
Layout table for additonal information
Responsible Party: Promomed, LLC
ClinicalTrials.gov Identifier: NCT05185284    
Other Study ID Numbers: FAV-052021
First Posted: January 11, 2022    Key Record Dates
Last Update Posted: January 11, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Promomed, LLC:
SARS-CoV-2
Areplivir
2019-nCoV
Favipiravir
Pneumonia
Coronavirus Infections
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Favipiravir
Remdesivir
Antiviral Agents
Anti-Infective Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action